Literature DB >> 11039613

Computed tomography and magnetic resonance imaging of patients with valvular heart disease.

A Rozenshtein1, L M Boxt.   

Abstract

Although computed tomographic (CT) and magnetic resonance (MR) evaluation of patients with valvular heart disease is almost never performed as a first line of diagnostic intervention, their performance does provide important morphologic and physiologic information concerning the etiology and the current status of the valvular dysfunction. Evaluation of chamber and great artery size as well as ventricular wall thickness provide the basis for diagnosing and analyzing severity of valvular heart disease. Furthermore, additional findings, including calcification and evidence of interstitial pulmonary edema, increase diagnostic sensitivity and confidence in diagnosis. MR examination has the advantage over CT of providing direct demonstration of the signal void jets of dysfunctional valves, as well as a means of quantitating regional and global ventricular function and severity of valvular pressure gradients.

Entities:  

Mesh:

Year:  2000        PMID: 11039613     DOI: 10.1097/00005382-200010000-00005

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  3 in total

1.  Mitral valve prolapse: a deeper look.

Authors:  Robert A Levine; Ronen Durst
Journal:  JACC Cardiovasc Imaging       Date:  2008-05

Review 2.  Cardiovascular sources of systemic embolism: detection and characterization using multidetector CT and MR imaging.

Authors:  Jiyoung Hwang; Yeon Hyeon Choe
Journal:  Int J Cardiovasc Imaging       Date:  2011-05-03       Impact factor: 2.357

3.  Surgically implantable magnetic resonance angiography coils improve resolution to allow visualization of blood flow dynamics.

Authors:  Tamara N Fitzgerald; Akihito Muto; Tiffany T Fancher; Peter B Brown; Karen A Martin; Bart E Muhs; Douglas L Rothman; R Todd Constable; Smita Sampath; Alan Dardik
Journal:  Ann Vasc Surg       Date:  2009-12-29       Impact factor: 1.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.